Form 4: Artivion Executive John E. Davis Executes Stock Options and Sells Shares

Chief Commercial Officer John E. Davis exercised stock options and sold shares of Artivion, Inc. on March 11, 2025, according to a Form 4 filing.

Summary

• On March 11, 2025, John E. Davis, Chief Commercial Officer of Artivion, Inc., exercised stock options to acquire 15,910 shares of common stock at a price of $21.55 per share.
• Simultaneously, Davis sold 15,100 shares of common stock at a weighted average price of $23.6125, with prices ranging from $23.14 to $23.89.
• These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on August 30, 2024.
• Following these transactions, Davis directly owns 208,778 shares of Artivion, Inc.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive, with no inherent positive or negative sentiment. It reflects routine activity.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are closely watched by investors for insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Executive compensation packages often include stock options as incentives, aligning management's interests with those of shareholders.
• Rule 10b5-1 trading plans are a standard practice allowing insiders to sell shares over a predetermined period, avoiding accusations of trading on non-public information.
• Comparable companies in the medical device industry, such as Medtronic or Boston Scientific, also have executives who regularly exercise stock options and sell shares.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the sales mitigates concerns about insider trading.

Key Dates